Page last updated: 2024-09-03

imatinib mesylate and Cockayne Syndrome

imatinib mesylate has been researched along with Cockayne Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bredrup, C; Bruland, O; Cristea, I; Houge, G; Høvding, G; Lee, S; McGaughran, J; Rødahl, E; Sapkota, D; Steen, VM; Stokowy, T; Tveit, KS; Xu, L	1

Other Studies

1 other study(ies) available for imatinib mesylate and Cockayne Syndrome

Article	Year
A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome. European journal of human genetics : EJHG, 2019, Volume: 27, Issue:4 Topics: Acro-Osteolysis; Adult; Aging; Apoptosis; Cockayne Syndrome; Female; Genetic Predisposition to Disease; HeLa Cells; Humans; Imatinib Mesylate; Limb Deformities, Congenital; Male; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Myofibromatosis; Phenotype; Phosphorylation; Progeria; Protein Interaction Maps; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction	2019

Article

Year

A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.

European journal of human genetics : EJHG, 2019, Volume: 27, Issue:4

Topics: Acro-Osteolysis; Adult; Aging; Apoptosis; Cockayne Syndrome; Female; Genetic Predisposition to Disease; HeLa Cells; Humans; Imatinib Mesylate; Limb Deformities, Congenital; Male; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Myofibromatosis; Phenotype; Phosphorylation; Progeria; Protein Interaction Maps; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction

2019